Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors.

ABSTRACT:

Purpose

The lead-203 (²⁰³Pb)/lead-212 (²¹²Pb) elementally identical radionuclide pair has gained significant interest in the field of image-guided targeted alpha-particle therapy for cancer. Emerging evidence suggests that ²¹²Pb-labeled peptide-based radiopharmaceuticals targeting somatostatin receptor subtype 2 (SSTR2) may provide improved effectiveness compared to beta-particle-based therapies for neuroendocrine tumors (NETs). This study aims to improve the performance of SSTR2-targeted radionuclide imaging and therapy through structural modifications to Tyr³-octreotide (TOC)-based radiopharmaceuticals.

Methods

New SSTR2-targeted peptides were designed and synthesized with the goal of optimizing the incorporation of Pb isotopes t

SUBMITTER: Lee D 

PROVIDER: S-EPMC10881741 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature